Thomas Grombacher
Darmstadt, HE, Germany
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 9 publications
First-in-Human Study of the Ataxia Telangiectasia and Rad3-Related (ATR) Inhibitor Tuvusertib (M1774) as Monotherapy in Patients with Solid Tumors.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: August 10, 2023
A New Class of Selective ATM Inhibitors as Combination Partners of DNA Double-Strand Break Inducing Cancer Therapies.
Journal: Molecular cancer therapeutics
Published: November 25, 2021
Mapping combinatorial drug effects to DNA damage response kinase inhibitors.
Journal: Nature communications
Published: October 27, 2021
Phase 1b study of berzosertib and cisplatin in patients with advanced triple-negative breast cancer.
Phase 1b study of berzosertib and cisplatin in patients with advanced triple-negative breast cancer.
Journal: NPJ breast cancer
Published: July 02, 2021
RosettaSX: Reliable gene expression signature scoring of cancer models and patients.
Journal: Neoplasia (New York, N.Y.)
Published: June 11, 2021
Pharmacologic Inhibitor of DNA-PK, M3814, Potentiates Radiotherapy and Regresses Human Tumors in Mouse Models.
Journal: Molecular cancer therapeutics
Published: July 30, 2019
Combining global and local measures for structure-based druggability predictions.
Journal: Journal of chemical information and modeling
Published: December 14, 2011
Showing 1-9 of 9
Last Updated: 09/26/2026